Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The American Heart Association recently published guidelines on how to clinically identify and categorize individuals with cardiovascular-kidney-metabolic (CKM) syndrome. The extent to which CKM syndrome prevalence and prognosis differ by sex remains unknown. This study aimed to examine the impact of sex on trends in prevalence over 30 years and the long-term prognosis of CKM syndrome in the United States.

Methods: We analyzed nationally representative National Health and Nutrition Examination Survey 1988 to 2018 data collected from 33 868 US adults (aged ≥20 years) who were under surveillance for all-cause mortality through December 31, 2019. We examined the sex-specific prevalence of CKM syndrome and sex-specific CKM associations with all-cause mortality.

Results: Of the 33 868 adults studied, the mean±SD age was 48.4±18.3 years with 52% women and 56% non-White. Overall prevalence of CKM syndrome increased steadily from 1988 to 2018 in both sexes, with a larger temporal rise in prevalent stage 3 CKM seen for men (from 18.9% to 22.4%) compared with women (from 13.9% to 15.2%). Over a median follow-up of 13.3 years, there were 8745 deaths. In the multivariable Cox regression analysis, worsening CKM severity was associated with all-cause mortality (<0.001 for both sexes), with greater magnitudes of risk seen in women (hazards ratio, 1.24-3.33) compared with men (hazards ratio, 0.85-2.60) across all stages (likelihood ratio test χ, 19.0; <0.001); results were similar for cardiovascular mortality (likelihood ratio test χ, 22.3; <0.001).

Conclusions: Women, compared with men, exhibited a lower prevalence of CKM stage 3 but experienced excess mortality risk across the spectrum of multisystem CKM dysfunction. These findings underscore the importance of identifying mechanisms underlying joint cardiovascular, kidney, and metabolic system pathophysiology to close a potentially widening sex disparities gap in multiorgan disease risk.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729504PMC
http://dx.doi.org/10.1161/ATVBAHA.124.321629DOI Listing

Publication Analysis

Top Keywords

ckm syndrome
20
ckm
8
1988 2018
8
33 868 adults
8
all-cause mortality
8
prevalence ckm
8
syndrome
6
sex differences
4
differences cardiovascular-kidney-metabolic
4
cardiovascular-kidney-metabolic syndrome
4

Similar Publications

Heterozygous Med13l mice recapitulate a developmental growth delay and craniofacial anomalies seen in MED13L syndrome.

Dev Dyn

September 2025

Department of Internal Medicine, Division of Cardiovascular Medicine, Francois M. Abboud Cardiovascular Research Center, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, Iowa, USA.

Background: Gene transcription is crucial for embryo and postnatal development and is regulated by the Mediator complex. Mediator is comprised of four submodules, including the kinase submodule (CKM). The CKM consists of MED13, MED12, CDK8, and CCNC.

View Article and Find Full Text PDF

Background: The association of the triglyceride glucose (TyG) index and related TyG metrics with obesity indices has been demonstrated to correlate with the incidence of cardiovascular disease (CVD). Nonetheless, this relationship has not been thoroughly investigated in patients with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3.

Methods: This study involved 7364 participants from the China Health and Retirement Longitudinal Study (CHARLS).

View Article and Find Full Text PDF

Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.

Heart Lung Circ

September 2025

Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,

Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.

View Article and Find Full Text PDF

The Impact of Cardiovascular-Kidney-Metabolic Syndrome Staging on Depression Risk: A National Study.

Heart Lung Circ

September 2025

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.

Background: Cardiovascular-kidney-metabolic (CKM) syndrome, recently defined by the American Heart Association, encompasses cardiovascular disease, chronic kidney disease, and metabolic disorders. However, its association with depression across different stages remains unclear.

Method: We analysed 4,097 adults from National Health and Nutrition Examination Survey 2005-2020.

View Article and Find Full Text PDF

Environment-wide association study of cardiovascular-kidney-metabolic syndrome based on NHANES 2013-2016.

Ecotoxicol Environ Saf

September 2025

School of Public Health, Capital Medical University, No.10 Xitoutiao, Youanmen Street, Beijing 100069, China; Beijing Key Laboratory of Environment and Aging, Capital Medical University, Beijing 100069, China. Electronic address:

Background: Environmental chemical exposure has emerged as an important risk factor for cardiometabolic and other chronic diseases. Cardiovascular-kidney-metabolic (CKM) syndrome conceptualizes the overlap of cardiovascular, kidney, and metabolic diseases as a systemic condition, providing a comprehensive framework for systematically identifying their risk factors. This study aimed to assess the associations between multiple environmental chemicals and CKM syndrome and to examine the potential mediating role of inflammation.

View Article and Find Full Text PDF